Skip to main content
. 2016 May 3;30(8):1229–1238. doi: 10.1097/QAD.0000000000001058

Fig. 1.

. Disposition of individuals at Week 48.

Fig. 1

AE, adverse event; MVC, maraviroc; DRV/r, darunavir/ritonavir; TDF/FTC, tenofovir/emtricitabine. aOf the AEs leading to discontinuation, 12 in each group were considered to be related to study treatment. bInvestigator decision to discontinue for lack of efficacy; individual did not necessarily meet criteria for protocol-defined virologic failure.